Michiel van der Heijden, MD, PhD

Michiel van der Heijden, MD, PhD, of Netherlands Cancer Institute

Articles by Michiel van der Heijden, MD, PhD

Cisplatin-Eligible, -Ineligible Population Analysis From EV-302

Michiel van der Heijden, MD, PhDAdvanced Urothelial Carcinoma | June 6, 2024

Drs. van der Heijden and Nizam weigh the EV-302 subanalyses of the cisplatin-eligible, -ineligible populations.